Tim Shannon, M.D.   |   Director

Timothy Shannon, M.D., is a General Partner at Canaan Partners where he focuses on early stage biopharmaceutical companies. He is chairman of the board of Arvinas and Spyryx Therapeutics and is a director at NextCure and Vivace. Prior successful companies include Civitas Therapeutics (acquired by Acorda), Novira Therapeutics (acquired by J&J) and CytomX (CTMX, IPO 2015). Dr. Shannon previously was president and Chief Executive Officer of CuraGen, a publicly traded biopharmaceutical company.  CuraGen merged with Celldex Therapeutics in 2009 where Dr. Shannon served on the board. Prior to that he was senior vice president of global medical development for Bayer’s Pharmaceutical Business Group. Dr. Shannon began his career as assistant professor of the pulmonary and critical care medicine at Yale University School of Medicine, received his M.D. form the University of Connecticut and his B.A. from Amherst College. • David Kabakoff, Ph.D.
Chairman
• Elaine V. Jones, Ph.D.
Director
• Chau Q. Khuong
Director
• Judith J. Li
Director
• Tim Shannon, M.D.
Director